Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong Donald Marvin?

Donald R. Marvin

President and Chief Executive Officer

Inocucor Technologies Inc

HQ Phone:  (438) 968-2100

Direct Phone: (303) ***-****direct phone

Email: d***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Inocucor Technologies Inc

7220 Frederick-Banting Suite 100

Montreal, Quebec,H4S 2A1

Canada

Company Description

Inocucor Technologies Inc., based in Montreal, is an ag biotech company that develops sustainable biological products for agriculture targeting the phyto-microbiome-the seeds, plants, root systems and the soil surrounding them. Inocucor's first-generation prod... more.

Find other employees at this company (23)

Background Information

Employment History

Chief Executive Officer and President

IdentiGEN Ltd.


Affiliations

Cairn Associates Inc

President and Chief Executive Officer


Microbiome Therapeutics LLC

Board Member


MBT

Board Member


Melior Discovery Inc

Board Member


VentureTalk Radio

Co-Founder


Tepnel Life Sciences PLC

Board Member


Orchid Cellmark Inc

Co-Founder, Chief Financial Officer and Senior Vice President of Corporate Development


NuMe Health LLC

Board Member


Nasdaq-quoted Orchid Biosciences

Founder


Education

B.S.

microbiology

Ohio State University


M.B.A.

microbiology

The Ohio State University


M.B.A.

organizational behavior and finance

Iona College


Web References(159 Total References)


Inocucor Technologies Announces First Close of $38.8M Series B Financing Led by TPG ART

www.prnewswire.com [cached]

"The specialty ag biologicals sector is one of agriculture's bright spots, answering the need for sustainable agriculture inputs that help growers improve yields and invigorate soil," said Inocucor's President and CEO Donald R. Marvin.
Marvin said independent studies using Synergro have shown increased yields in strawberries of 30 percent or more. Yields for other high-value produce crops using a Synergro-based treatment program have increased from the high single digits to between 40 and 50 percent.


www.clearag.com

Don Marvin, President & CEO, INOCUCOR, USA


news.agropages.com

Inocucor President and CEO Donald R. Marvin announced results of the field trials during a presentation recently at Agri Innovation Forum in Winnipeg, Manitoba....


inocucor.com

Donald Marvin, Inocucor president and CEO, tells GAI News that the double nod from the Canadian Food Inspection Agency was two years in the making.
"With these approvals we can move forward with the commercialization of the company's Synergro Free product targeting commodity row crops this coming growing season. Synergro, our product for high-value produce, we can begin selling immediately," said Marvin, adding that the company has back orders to fill. Andree-Lise Méthot, founder and managing partner of Montreal-based Cycle Capital Management, an early investor in Inocucor, tells GAI News Cycle was initially responsible for bringing Marvin, a transplant from the pharmaceutical industry, to the company. In addition to Marvin, Cycle introduced the company to Jim Blome, chief executive at Bayer CropScience, who also chairs Inocucor's Board of Directors. "Don has an amazing team around him, very savvy people in the ag sector, in [intellectual property] in terms of genetics and other things. He put together a team and it works very well with his investors including Cycle Capital and the people that we bring in, and I think he is really personally committed," she said. "Independent studies have shown increased yields in strawberries of 30 percent or more," said Marvin, adding that yields for other high-value produce crops using a Synergro-based treatment program have jumped anywhere from the high-single digits to between 40 and 50 percent, depending on the particular crop. We are pleased with the results," said Marvin. Plus they have limited tools in their toolbox to treat crops because they are organic farmers," said Marvin, adding that when conventional growers began noticing the yield pops among their organic peers they too starting asking for the product. That's how we do it in the U.S.," said Marvin. Marvin also anticipates that the pair of U.S.-based family offices that backed the company in June 2016 also may commit additional capital for the Series B. The lead investor in the Series B round, however, will be a first-time investor in Inocucor. "They will likely be joined by another new investor or two to fully complete the Series B financing," said Marvin, adding that he expects to make a formal announcement in the coming weeks. The privately held company is not yet profitable as Inocucor continues to plow revenue from the sale of its products back into the business. Marvin expects, however, that in the next couple of years Inocucor will indeed become profitable. Meanwhile, revenue growth from 2016 to 2017 is pegged at 75 percent to 80 percent of the previous year given the wider distribution and international expansion ahead. A lot is going on in the soybean area for us," said Marvin, adding that the company's Western Europe expansion is expected to be in Spain's high-value produce market. "Bio-stimulants are well accepted and adapted in Western Europe and also heavily used in Spain's high-value produce growing regions," he noted. Indeed, part of the growth strategy at Inocucor for capturing market share is by strategic M&A, and depending on the timing Marvin could be seated on either side of the deal table. "You will see us make acquisitions along the way in the specialty ag biologicals space to drive market leadership in this rapidly growing sector," said Marvin. As for an exit strategy, the end game could be one of several possibilities said Marvin, including a potential sale to a strategic buyer. "There is a lot of value to build under the curve, and we're in it for the long run. While we have very patient investors, at some point you have to give all stakeholders a pattern of liquidity and for me it's really a clinical process one goes through to achieve that objective," said Marvin, adding that there's no rush on the company's part to get there.


www.producegrower.com

Through the company's proprietary fermentation process, these microbial products and their active bio-molecules give farmers new tools that naturally improve soil health and increase crop yields," said Donald R. Marvin, president and CEO of Inocucor.
Marvin said Inocucor has documented four years of enhanced yield increases and improved soil health through field trials and demonstrations conducted with commercial partners and customers in the U.S. and Canada.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory